Europe Influenza Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 2,000.00$ 6,900.00

Europe Influenza Market: Drug Class (Anti-viral drugs, Interferons, Vaccines), Route Of Administration (Oral, Parenteral, Others), By End User ( Hospital pharmacies Retail pharmacies Others) And Geography

$ PRICE - $ 2,000.00$ 6,900.00
Clear selection
Clear
$ PRICE - $ 2,000.00$ 6,900.00
FacebookTwitterLinkedinEmail

Report

Description

Europe Influenza Market size was valued at USD 1.39 billion in 2021 and is expected to reach USD 2.6 billion by 2028, at a CAGR of 9.5% during the forecast period 2022-2028. Influenza is an upper respiratory tract disease and is caused by the influenza virus. The influenza virus is mainly three types namely Influenza A, Influenza B, and Influenza C. Influenza is a communicable disease, spread through a flu cough, droplets from the infected people, sneeze or talks. The common symptoms occur in influenza patients are chills, cough, running nose, sore throat, body aches, headache, fatigue, some cases people may have vomiting and diarrhea. The complication of the disease may include ear infections, bacterial pneumonia, dehydration, sinus infections, and sometimes it leads to congestive heart failure, and asthma. Influenza commonly occurs in the geriatric population and children with less than % years of age.  The infection may be confirmed by testing the sputum, nose, or throat for the virus. A number of rapid tests are available however polymerase chain reaction that detects the virus’s RNA is more accurate. Several international players in Europe are actively involved in the development of vaccines and drugs for influenza treatment to increase its market share. Vaccines are majorly preferred for the influenza treatment which is key revenue contributor for the growth of market share. Launching of new products, technological innovations, and approvals from European Medical Agency for various drugs might fuel the growth of the market. For instance, in July 2016, Sanofi Pasteur MSD announced the approval of the latest addition to its family of influenza vaccines in the UK. Similarly, during 2009, three vaccines Celvapan, Pandemrix, and Focetria were authorized as the mock-up vaccines and converted into the pandemic-influenza vaccines after the identification of A/H1N11 flu strain. Similarly, two vaccines Humenza and Arepanrix were authorized using the emergency procedure and contributed renewed interest in the Europe influenza market.

Europe Influenza Market

MARKET SUMMARY
-
9.5%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 9.5%

Europe Influenza Market

  • This report gives a comprehensive outlook on europe influenza market with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa.
  • The report gives historical, current, and future market sizes (US$ Mn) on the basis of drug class, route of administration, end user and region.
Key Players
  • AstraZeneca
  • Abbott Laboratories
  • BioCryst Pharmaceuticals
  • Emergent Biosolutions
  • GlaxoSmithKline

 

Europe Influenza Market

DRIVERS AND RESTRAINTS

The Europe Influenza market is growing at a significant CAGR due to an increase in the geriatric population. An increase in vaccination awareness, rising investment by companies in research and development activities, and an increasing number of immunization programs organized by the government are the major factors fuelling the growth of market over the forecast period. The major market players have great pipeline products, Initiatives by government bodies such as WHO to ECDC to control and prevent influenza, technological advancements in diagnostic tests also fuel the growth of the market over the forecast period. However, lack of required funding, limited opportunities for the production of vaccines, and stringent regulatory policies for new product approvals might hamper the growth of the market. Due to limitations in current technologies, the lengthy production times (approximately seven months), increasing prices of Influenza diagnostic kits, and difficulties in the storage of inventory also hinder the Europe influenza market.


Europe Influenza Market

Europe holds a dominant share in the global influenza market. The largest share is attributed to rising awareness regarding the influenza virus and disease, raising investment by companies in research and development, and increasing number of immunization programs organized by the government are some of the factors driving the Europe Influenza Market. The increase in the prevalence of influenza in the European region is a major driving factor for the growth of European Influenza market. According to EMEA, approximately 15,000 people die of the severe consequence of influenza. Similarly, change in lifestyle, food habituations, and climatic conditions in European countries such as Austria, Germany, U.K., Spain, and Switzerland, among others also increase the growth of Europe Influenza market.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Developments

  • In June 2016, new four-strain influenza vaccine, Vaxigriptetra, regulatory dossier from Sanofi Pasteur approved in Europe

Key

Features of the Report

Europe Influenza Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content

1.Executive summary

  1. Europe Influenza Market Introduction

2.1. Europe Influenza Market – Taxonomy

2.2. Europe Influenza Market –Definitions

2.2.1. Drug Class Type

2.2.2. Route of Administration

2.2.3. Distribution Channel

  1. Europe Influenza Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Europe Influenza Market Dynamics – Factors Impact Analysis

3.6. Europe Influenza Market – Regulations

3.7. Europe Influenza Market – Product Innovations

  1. Europe Influenza Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026

4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Oppurtunity Analysis

  1. Europe Influenza Market, By Drug Class, 2015 – 2019 and Forecast, 2020 – 2026

5.1. Anti-Viral Drugs

5.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3. Market Opportunity Analysis

5.1.3.1. Zanamivir

5.1.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.3. Market Opportunity Analysis

5.1.3.4. Oseltamivir

5.1.3.5. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.3.6. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.7. Market Opportunity Analysis

5.1.3.8. Amantadine

5.1.3.9. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.3.10. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.11. Market Opportunity Analysis

5.1.3.12. Rimantadine

5.1.3.13. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.3.14. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.15. Market Opportunity Analysis

5.1.3.16. Others

5.1.3.17. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.3.18. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.19. Market Opportunity Analysis

          5.2. Vaccines

5.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.3. Market Opportunity Analysis

5.2.3.1. Trivalent

5.2.3.2. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.2.3.3. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.3.4. Market Opportunity Analysis

5.2.3.5. Quadrivalent

5.2.3.6. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.2.3.7. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.3.8. Market Opportunity Analysis

  1. Europe Influenza Market Forecast, By Route of Administration, 2015 – 2019 and Forecast, 2020 – 2026

6.1. Oral

6.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.1.3. Market Opportunity Analysis

6.2. Parenteral

6.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.2.3. Market Opportunity Analysis

6.3. Others

6.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.3.3. Market Opportunity Analysis

  1. Europe Influenza Market Forecast, By Distribution Channel, 2015 – 2019 and Forecast, 2020 – 2026

7.1. Hospital pharmacies

7.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.1.3. Market Opportunity Analysis

7.2. Retail pharmacies

7.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.2.3. Market Opportunity Analysis

7.3. Others

7.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.3.3. Market Opportunity Analysis

  1. Europe Influenza Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026

8.1. Drug Class Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

8.1.1. Anti-viral drugs

8.1.1.1. Zanamivir

8.1.1.2. Oseltamivir

8.1.1.3. Amantadine

8.1.1.4. Rimantadine

8.1.1.5. Others

8.1.1.6. Interferons

8.1.2. Vaccines

8.1.2.1. Trivalent

8.1.2.2. Quadrivalent

8.2. Route of Administration Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.2.1. Oral

8.2.2. Parenteral

8.2.3. Others

8.3. Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Others

8.4. Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.4.1. Germany

8.4.2. UK

8.4.3. France

8.4.4. Spain

8.4.5. Italy

8.4.6. Russia

8.4.7. Poland

8.4.8. Rest of Europe

8.5. Europe Influenza Market – Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel and Country, 2018 – 2024

8.6. Europe Influenza Market Dynamics – Trends

  1. Competition Landscape

9.1. Strategic Dashboard of Top Market Players

9.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

9.2.1. AstraZeneca (UK)

9.2.2. F. Hoffmann-La Roche (Switzerland)

9.2.3. GlaxoSmithKline plc. (UK)

9.2.4. Novartis AG (Switzerland)

9.2.5. Sanofi (France)

9.2.6. Seqirus (UK)

9.2.7. Protein Sciences Corporation (U.S.)

9.2.8. Emergent Biosolutions (U.S.)

9.2.9. BioCryst Pharmaceuticals.Inc (U.S.)

9.2.10. Abbott Laboratories (U.S.)

  1. Research Methodology
  2. Key Assumptions and Acronyms

Report

Company Profile

  • AstraZeneca (U.K.)
  • F. Hoffmann-La Roche (Switzerland)
  • GlaxoSmithKline Plc. (U.K.)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Protein Sciences Corporation (U.S.)
  • Emergent Biosolutions (U.S.)
  • BioCryst Pharmaceuticals.Inc. (U.S.)
  • Abbott Laboratories Inc. (U.S.)

Description

Europe Influenza Market size was valued at USD 1.39 billion in 2021 and is expected to reach USD 2.6 billion by 2028, at a CAGR of 9.5% during the forecast period 2022-2028. Influenza is an upper respiratory tract disease and is caused by the influenza virus. The influenza virus is mainly three types namely Influenza A, Influenza B, and Influenza C. Influenza is a communicable disease, spread through a flu cough, droplets from the infected people, sneeze or talks. The common symptoms occur in influenza patients are chills, cough, running nose, sore throat, body aches, headache, fatigue, some cases people may have vomiting and diarrhea. The complication of the disease may include ear infections, bacterial pneumonia, dehydration, sinus infections, and sometimes it leads to congestive heart failure, and asthma. Influenza commonly occurs in the geriatric population and children with less than % years of age.  The infection may be confirmed by testing the sputum, nose, or throat for the virus. A number of rapid tests are available however polymerase chain reaction that detects the virus’s RNA is more accurate. Several international players in Europe are actively involved in the development of vaccines and drugs for influenza treatment to increase its market share. Vaccines are majorly preferred for the influenza treatment which is key revenue contributor for the growth of market share. Launching of new products, technological innovations, and approvals from European Medical Agency for various drugs might fuel the growth of the market. For instance, in July 2016, Sanofi Pasteur MSD announced the approval of the latest addition to its family of influenza vaccines in the UK. Similarly, during 2009, three vaccines Celvapan, Pandemrix, and Focetria were authorized as the mock-up vaccines and converted into the pandemic-influenza vaccines after the identification of A/H1N11 flu strain. Similarly, two vaccines Humenza and Arepanrix were authorized using the emergency procedure and contributed renewed interest in the Europe influenza market.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX